Publications

2024

  1. Holter-Chakrabarty J, McNally L, Levine J, Ferrara J, Vesely SK, Kanakry CG, Garwe T, Han Z, Pandey M, Glover J, Wen Y. 18F-FLT PET and Blood-based Biomarkers for Identifying Gastrointestinal Graft versus Host Disease after Allogeneic Cell Transplantation. Radiology: Imaging Cancer. 2024 Dec 13;7(1):e240096.

2023

  1. Han Z*., Han R*., Lan X*., Ren H., Aafreen S., Wang W., Hou Z., Zhu T., Qian A., Han X. and Koehler R.C. Improving outcomes in intracerebral hemorrhage through microglia/macrophage-targeted IL-10 delivery with phosphatidylserine liposomes. Biomaterials, p.122277. (2023) (*Denotes equal contribution).
  2. Han Z., MacCuaig W.M., Gurcan M.N., Claros-Sorto J., Garwe T., Henson C., Holter-Chakrabarty J., Hannafon B., Chandra V., Wellberg E. and McNally L.R.. Dynamic 2-deoxy-D-glucose-enhanced multispectral optoacoustic tomography for assessing metabolism and vascular hemodynamics of breast cancer. Photoacoustics, p.100531. (2023)

2022 and previous

  1. Han Z*, Dennahy IS*, MacCuaig WM, Chalfant HM, Condacse A, Hagood JM, … & McNally LR (2022). Nanotheranostics for Image-Guided Cancer Treatment. Pharmaceutics, 14(5), 917. (*Denotes equal contribution).
  2. Han Z, Chen C, Xu X, et al. Dynamic contrast‐enhanced CEST MRI using a low molecular weight dextran[J]. NMR in Biomedicine. e4649 (2021).
  3. Han Z, Liu S, Pei Y, et al. Highly efficient magnetic labelling allows MRI tracking of the homing of stem cell‐derived extracellular vesicles following systemic delivery. Journal of Extracellular Vesicles.10(3): e12054 (2021).
  4. Han Z, & Liu G. CEST MRI trackable nanoparticle drug delivery systems. Biomedical Materials. In press. (2021).
  5. Chen Z, Han Z, & Liu G. Repurposing Clinical Agents for Chemical Exchange Saturation Transfer Magnetic Resonance Imaging: Current Status and Future Perspectives. Pharmaceuticals, 14(1), 11 (2021).
  6. Chen L*, Liu J*, Chu C*, Han Z*, Yadav N, Xu J, Bai R, Staedtke V, Pearl M, Walczak P, van Zijl P, Janowski M, Liu G. Deuterium oxide as a contrast medium for real-time MRI-guided endovascular neurointervention. Theranostics, 2021, 11(13): 6240. (*Denotes equal contribution).
  7. Qiao P, Ayat N R, Vaidya A, Gao S, Sun W, Chou S, Han Z, Gilmore H, Winter JM, Lu Z-R. Magnetic resonance molecular imaging of extradomain B fibronectin improves imaging of pancreatic cancer tumor xenografts. Frontiers in oncology, 2020, 10: 2164.
  8. Zhang J, Yuan Y, Han Z, Li Y, van Zijl PCM, Yang X, Bulte JWM, Liu G. Detecting acid phosphatase enzymatic activity with phenol as a chemical exchange saturation transfer magnetic resonance imaging contrast agent (PhenolCEST MRI). Biosensors and Bioelectronics. 141, 111442 (2020)
  9. Cai X, Zhang J, Lu J, Long Yi, Han Z, Zhang S, Yang X, Liu G. N‐aryl amides as chemical exchange saturation transfer magnetic resonance imaging contrast agents. Chemistry–A European Journal, 2020, 26(51): 11705-11709
  10. Chen Z, Li Y, Airan R, Han Z, Xu J, Chan KWY, Xu Y, Bulte JWM, Van Zijl PCM, McMahon MT, Zhou S, Liu G. CT and CEST MRI bimodal imaging of the intratumoral distribution of iodinated liposomes. Quantitative imaging in medicine and surgery 9 (9), 1579 (2019).
  11. Han Z, Zhang S, Fujiwara K, Zhang J, Li Y, Liu J, van Zijl PCM, Lu ZR, Zheng L, Liu G. An extradomain-B fibronectin-targeted dextran-based CEST MRI probe for detecting pancreatic cancer. Bioconjugate chemistry. 30 (5), 1425-1433 (2019).
  12. Han Z, Li Y, Zhang J, Liu J, Chen C, van Zijl PCM, Liu G. Molecular imaging of deoxycytidine kinase activity using deoxycytidine-enhanced CEST MRI. Cancer research. 79 (10), 2775-2783 (2019).
  13. Han Z, Sergeeva O, Roelle S, Cheng H, Gao S, Li Y, Lee Z, Lu ZR. Preparation and evaluation of ZD2 peptide 64Cu-DOTA conjugate as a positron emission tomography probe for detection and characterization of prostate Cancer. ACS Omega. 4 (1), 1185-1190 (2019).
  14. Han Z, Liu G. Sugar-based biopolymers as novel imaging agents for molecular magnetic resonance imaging. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 11:e1551 (2019).
  15. Heo HY, Han Z, Jiang S, Schär M, van Zijl PCM, Zhou J. Quantifying amide proton exchange rate and concentration in chemical exchange saturation transfer imaging of the human brain. Neuroimage. 189: 202-213 (2019).  
  16. Zhang J, Han Z, Lu J, Li, Liao X, van Zijl PCM, Yang X, Liu G. Triazoles as T2-exchange magnetic resonance imaging contrast agents for the detection of nitrilase activity. Chemistry-A European Journal. 24(56): 15013-15018 (2018).
  17. Sun D, Sun Z, Jiang H, Vaidya A.M, Xin R, Ayat NR, Schilb AL, Qiao P.L, Han Z, Naderi A, Lu ZR. Synthesis and Evaluation of pH-Sensitive Multifunctional Lipids for Efficient Delivery of CRISPR/Cas9 in Gene Editing. Bioconjugate chemistry. In press (2018).
  18. Liu J, Han Z, Chen G, Li Y, Zhang J, Xu J, van Zijl PCM, Zhang S, Liu G. CEST MRI of sepsis‐induced acute kidney injury. NMR in Biomedicine. 31 (8), e3942 (2018).
  19. Han Z, Cheng H, Parvani JG, Zhou Z, Lu ZR. Magnetic resonance molecular imaging of metastatic breast cancer by targeting extradomain-B fibronectin in the tumor microenvironment. Magnetic Resonance in Medicine. 79 (6), 3135-3143 (2018)
  20. Li Y, Qiao Y, Chen H, Bai R, Staedtke V, Han Z, Xu J, Chan K.W.Y., Yadav N, Bulte J.W.M., Zhou S, van Zijl P.C.M, and Liu G. Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magnetic Resonance in Medicine. 79(2): 1001-1009 (2017).
  21. Han Z, Wu X, Roelle S, Chen C, Schiemann WP and Lu ZR, Targeted gadofullerene for sensitive magnetic resonance imaging and risk-stratification of breast cancer. Nature Communications. 8(1): 692 (2017)
  22. Li Y*, Han Z*, Roelle S, DeSanto A, Sabatelle R, Schur R, and Lu ZR. Synthesis and assessment of peptide Gd-DOTA conjugates targeting extradomain B Fibronectin for magnetic resonance molecular imaging of prostate cancer. Molecular Pharmaceutics. 14(11): 3906-3915 (2017). (*Denotes equal contribution).
  23. Han Z, Li Y, Roelle S, Zhou Z, Liu Y, Sabatelle R, DeSanto A, Yu X, Zhu H, Magi-Galluzzi C, and Lu ZR. A targeted contrast agent specific to an oncoprotein in tumor microenvironment with the potential for detection and risk stratification of prostate cancer with MRI. Bioconjugate Chemistry. (2017)
  24. Han Z, and Lu ZR. Targeting fibronectin for cancer imaging and therapy. Journal of Materials Chemistry B. 5(4): 639-654 (2017). (Cover story, 2016 hot paper of the journal)
  25. Wu X*, Han Z*, Schur RM, Lu ZR. Targeted mesoporous silica nanoparticles delivering arsenic trioxide with environment sensitive drug release for effective treatment of triple negative breast cancer. ACS Biomaterials Science & Engineering. 2(4): 501-507(2016). (*Denotes equal contribution).
  26. Zhou Z, Han Z, and Lu ZR. A targeted nanoglobular contrast agent from host-guest self-assembly for MR cancer molecular imaging. Biomaterials. 85: 168-179 (2016).
  27. Zhou Z, Quatish M, Han Z, Schur RM, Wilson DL, Lu ZR, MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent. Nature communications 6: 7984 (2015).
  28. Han Z, Zhou Z, Shi X, Wang J, Wu X, Sun D, Chen Y, Zhu H, Magi-Galluzzi C, and Lu ZR. EDB fibronectin specific peptide for prostate cancer targeting. Bioconjugate Chemistry. 26(5): 830-838 (2015).